ILUMYA
PeakmAbtildrakizumab-asmn
BLAINJECTIONINJECTABLE
Approved
Mar 2018
Lifecycle
Peak
Competitive Pressure
30/100
Data completeness
4/8 — Partial
ILUMYA (tildrakizumab-asmn) is interleukin-23 antagonists [moa]. First approved in 2018.
Drug data last refreshed 2d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ILUMYA (tildrakizumab-asmn) is a monoclonal antibody that selectively antagonizes interleukin-23 (IL-23), a key cytokine in immune-mediated inflammatory diseases. Approved by the FDA on March 20, 2018, it is indicated for plaque psoriasis and other IL-23-driven conditions. The drug represents a targeted approach to dermatologic and systemic inflammatory disorders by blocking the IL-23 signaling pathway, positioning it within the growing class of biologic immunomodulators for chronic inflammatory conditions.
$0.0BPart D
Mechanism of Action
Interleukin-23 Antagonists
Pharmacologic Class:
Interleukin-23 Antagonist
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
ILUMYA creates opportunities for brand managers, medical science liaisons (MSLs), and sales representatives focused on dermatology and rheumatology specialties, though the modest Part D penetration suggests a smaller commercial footprint than blockbuster biologics. Critical skills include deep understanding of IL-23 biology, competitive positioning against other biologic classes, payer negotiation, and patient-support program management. No linked open positions are currently available according to the data provided.
External Resources
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.